Skip to main content
. 2017 Feb 10;31(10):2151–2160. doi: 10.1038/leu.2017.8

Figure 3.

Figure 3

CD5CAR NK-92 cells specifically target and eliminate aggressive CD5+ primary T-ALL and T-lymphoma cells. (a) At a 2:1 E:T ratio, the CD5CAR NK-92 cells specifically lyse the CD5+ populations of the primary T-ALL sample (T-ALL 2) and the primary T-lymphoma samples (PT4—unclassified PTCL and SPT-1—Sezary Syndrome from bone marrow aspirate) after overnight co-culture using the indicated CD markers for gating. CD5CAR NK-92 cells also target and eliminate UCB-derived T-cells expressing CD5. All patient samples express a significant amount of CD5. (b) At a 5:1 E:T ratio, the CD5CAR NK-92 cells eliminate virtually all CD5+ populations derived from primary patient samples. (c) CD5CAR NK-92 cells target and lyse CD5+ MCL cell line JeKo and CD5+ primary mantle cell patient sample L3-G. Co-cultures were carried out at the indicated E:T ratios. (d) Absolute cell counts of CD5CAR NK-92 cells and vector control NK-92 cells against primary PTCL, T-ALL, mantle cell and normal UCB T-cells. Control and CD5CAR treatments are delineated in red and blue, respectively, with effector and target cells counted after culture.